Voluntis, listed on Euronext Paris and a leader in digital therapeutics, has completed a capital increase through private placement without preferential subscription rights for a total amount of € 5.9 million.
The securities were subscribed by quality European investors, mostly specialised in the health sector, including Debiopharm Innovation Fund, corporate fund of the Swiss company Debiopharm and Indigo, personal holding company of Eric Carreel, Chairman and co-founder of Withings, which has strengthened its position. The issue price of the new shares was set at
€ 4.43 per share, ie a discount of 15% compared to the average price weighted volume of the last 3 trading sessions preceding its setting.
“We were very happy to advise Voluntis in this structuring capital operation, which will enable it to strengthen its financial resources, particularly for its R&D and to continue to carry out its strategic plan with leaders in the pharmaceutical industry” explains Christine Lambert-Goué, Corporate & Investment Bank Director at Banque Delubac & Cie.
The offering was led by Banque Delubac & Cie - CIB as leader, adviser and global coordinator of the transaction.